Save up -80% on Dexrazoxane
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Zinecard
|price without discount in nearest pharmacy. Price may vary.|
We offer free Dexrazoxane coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Dexrazoxane every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Dexrazoxane volume of distribution
* 9 to 22.6 L/m^2
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Dexrazoxane
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.
Dexrazoxane mechanism of action
The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protective through its inhibitory effect on topoisomerase II.
Dosage forms of Dexrazoxane
|Powder for concentrate and diluent for solution for infusion||Intravenous use||20 mg/ml|
|Injection, powder, lyophilized, for solution||intravenous||250 mg/25mL|
Mylan Institutional LLC
Humans and other mammals
Indication of Dexrazoxane
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
Toxicity of Dexrazoxane
Intraperitoneal, mouse LD sub 10 /sub = 500 mg/kg. Intravenous, dog LD sub 10 /sub = 2 gm/kg.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Dexrazoxane on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.